TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Impact of STAR on clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bone lesions detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in PGC1a Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PPARb Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Protein degradation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of coagulopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute Platelet levels < 150,000/mm3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute Fibrinogen levels < 150 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of pulmonary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death-censored graft loss
Endpoint domain: Mortality/survival
Primary endpoint: Clinical indication biopsy-proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: De novo donor specific antibody development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: first attempt success rate of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from Baseline AOFAS score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline SF-36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average morning/evening reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Integrity of IVC Filter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skin Carotenoid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Survival with good neurological outcome for activities of daily living (CPC 1-2)
Endpoint domain: Mortality/survival
Primary endpoint: MACE: death, myocardial infarction, clinically evident bleeding (BARC> 2) or ventricular arrhythmias
Endpoint domain: Mortality/survival
Primary endpoint: Correct identification of disease presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of alvocidib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI Z-score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: vascular endothelial growth factor (VEGF) aqueous levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pigment epithelium-derived factor (PEDF) aqueous levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-hour oral glucose tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fasting blood insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of post-operative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of treatment with modafinil
Endpoint domain: Adverse events/effects
Primary endpoint: Spirometric FVC Values at Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spirometric FEV1 Values at Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Spirometric FEF Values at Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Life Simple 7 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maintenance of the radial length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph Node Involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in allergic symptom scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Serum [IGF-1] (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Serum [GH] (pg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Serum [IGFBP-3] (ng/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Condom failure (breakage or slippage)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of medically confirmed urinary tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: lesion recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intentional presence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knowing the person
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With a Positive Anti-BMN 701 Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With a Positive Anti-BMN 701 Antibody Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TGF-Beta expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver stiffness measurement by Transient Elastography >=8 kPa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correlation of stem cell markers on CTCs with response to therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge in Child and Adolescents Mental Health
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Beliefs and attitudes in Child Mental Health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Colorectal adenoma detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Manifest Refraction Cylinder (MRCYL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eyes With Best Corrected Distance Visual Acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Endothelial Cell Count (ECC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of surgical interventions avoided
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of core movement control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of proprioception of the core
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of neuromuscular control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in exhaled breath condensate pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity of arsenic and temozolomide during radiation therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Clarithromycin susceptibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity and Dystonia grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Phase lag entropy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost evaluation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentages of latent versus replicative EBV profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Post-operative Opioid Pain Medication Usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visual Pain Score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with ≤ 4 periodontal sites with PD ≥ 5 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red Blood Cell phospholipid weight percent of Docosahexaenoic Acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cognitive Measures - Executive Function, Language Development, and Behavior Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: H Pylori Positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Biopsychomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Treatment Benefit
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain Score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distress and Risk Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptomatic medication use reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: IIEF Q3 & Q4
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Facial Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health-related Quality of Life (QoL) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Comparison of Bios device readings and glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Experiencing Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Health Related Quality of Life (HRQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with clinically relevant bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: New Digital Ulcers (DU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to full enteral nutrition (FEN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Number of Grade 3 Adverse Events Probably Related to the Vaccine Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HIV-1 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Self-reported unprotected sex with HIV negative/unknown partner
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Pharmacokinetic variables for S-warfarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patient Participants' Acceptance of PGx Services Offered in Community Pharmacy Setting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Patient Participants With High Medication Adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patient Participants Who Reported Understanding of Implications of Test Results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of Participant Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Analyte Serum Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Analyte Serum Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination Half-life in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of esophageal atresia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants with Treatment-Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Bayley Scales of Infant and Toddler Development - Third Edition (BSITD-III) Cognitive Raw Score Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Time with Hemoglobin Levels Between 9 to 11 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Loneliness as assessed by the De Jong Gierveld Loneliness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Loneliness as Assessed by the UCLA Short Scale for Measuring Loneliness in Large Surveys
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiovascular Events (Composite Myocardial Infarction, Stroke, Cardiovascular Mortality)
Endpoint domain: Mortality/survival
Primary endpoint: Non-Cardiovascular Disease Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Hip Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Glucose disorder prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of clean and clean-contaminated cases
Endpoint domain: Adverse events/effects
Primary endpoint: Change in stool bacterial percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in fecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in urine Claudin-3 and I-FABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tibiotalar Joint Angle Kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging biomarker of progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Imaging biomarker that discriminates different neurodegenerative diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Heart Failure Hospitalization/ ED Visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Airway pressure Ppeak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Airway pressure Pplat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sperm concentration in semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Sperm motility in semen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cognitive function as measured by ADAS-Jcog
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Unexpected Events
Endpoint domain: Adverse events/effects
Primary endpoint: tacrolimus intra-subject variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AM levels in plasma and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RF duration to succeed in PVs isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects who are pain-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects who are nausea-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in S. Aureus Log CFU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Phenotypical markers of enzymes and transporter activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of major cardiac events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cumulative Incidence of bleeding and major vascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Digital behavior parameters
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Percent Predicted Slow Vital Capacity (SVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in metabolic control (phenylalanine) over Evaluation Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in gastrointestinal quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in adherence to recommended amounts of PKU sphere
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PROMIS Depression-SF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NeuroQOL Positive Affect and Wellbeing-SF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Professional identity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Career self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Magnitude of the Serum Antibody Response by Hemagglutination-inhibition (HAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Magnitude of the Serum Antibody Response by Microneutralization (MN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity of the Serum Antibody Response by Hemagglutination-inhibition (HAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specificity of the Serum Antibody Response by Microneutralization (MN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean percentage change in treated fibroid perfused volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Event Rate to 30 Days post-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Mitral regurgitation grade and change from baseline to 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Device Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: decline of urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: VO2max change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Attitude Toward Diabetes - Diabetes Empowerment Scale (DES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Toffee Mask Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Toffee Mask Comfort
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Toffee Mask Treatment Seal Performance-Subjective
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of screening strategy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: LV End systolic dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LV End diastolic dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Relative risk of first asthma diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PVC recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression Free Survival (PFS) at 12 Months
Endpoint domain: Mortality/survival
Primary endpoint: Overall Image Quality of Magnetic Resonance Elastography (MRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Patterns of autoimmune chronic liver diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Tumor Blood Flow/Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Tumor Hypoxic Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fluorescence of protoporphyrin IX (PpIX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes